GREENVILLE, S.C., April 11, 2023 (Newswire.com) - AGFA HealthCare, a leading provider of Enterprise Imaging solutions, is proud to announce that it has joined the Amazon Web Services (AWS) Partner Network (APN) to scale up the global availability of AGFA Enterprise Imaging (AGFA EI) VNA and XERO^® Universal Viewer on the cloud. The APN is a global community of AWS Partners that leverage programs, expertise, and resources to build, market, and sell customer offerings.

At HIMSS23, visitors can discover how AGFA HealthCare is working with AWS to allow healthcare networks across the globe to outsource data protection and security responsibilities and keep the VNA's scalability elastic.

• The scalability of the cloud VNA can help AGFA HealthCare's customers improve the predictability of costs and control, especially not having to deal with infrastructure and storage and end-of-life issues, while supporting evolving needs in terms of changing image volumes or the health system's growth through acquisitions and mergers.
• Simplified in-house IT administration reduces IT burdens.

"Joining the AWS Partner Network allows us to leverage a wealth of programs, expertise and resources to build technical solutions that keep us in the forefront of meeting the ongoing IT needs of our customers globally. The explosion in medical imaging data requires new solutions for handling, storing and protecting data, while making it seamlessly available to the people who need it,"  says Nathalie McCaughley, President, AGFA HealthCare.

"By supporting our EI VNA and XERO Universal Viewer on the cloud with AWS, we can help health systems to face their imaging challenges, including the difficulties of managing data protection and security, ensuring that infrastructure remains scalable, attracting and retaining skilled IT talents, and predicting costs," added Mark Burgess, President North America, AGFA HealthCare. 

Secure data availability with predictable costs

By simplifying image data management and consolidating even the most isolated data, while reducing storage, archiving and back-up costs, the AGFA EI VNA offers health systems and hospitals true business transformation opportunities. The AGFA HealthCare XERO Universal Viewer, which delivers an HTML5-based zero footprint user interface and seamless Single Sign On (SSO) integration capabilities, enables the imaging data to be accessed and shared across the enterprise, even if the on-premises PACS goes down.

Hosting the AGFA EI VNA and XERO Universal Viewer on AWS helps to close the infrastructure gap in the health system's image management, further enhancing data availability and delivering world-class security, while making costs more predictable and simplifying in-house IT administration. Furthermore, as the image volume increases or the health system expands, the VNA delivers the needed elasticity and scalability.

As an APN member, AGFA HealthCare joins a global network of 100,000 AWS Partners from more than 150 countries working with AWS to provide innovative solutions, solve technical challenges, support customer successes, and deliver value for mutual customers.

Discover how AGFA HealthCare is working with AWS to help your organization close the infrastructure gap in your organizations' image management at HIMSS23, booth #1902, Chicago. 

Join AGFA HealthCare in the AWS Theater (Booth #2056) on April 19 at HIMSS23 to learn how to Create the Community Health Record for Imaging. Learn how the AGFA HealthCare Enterprise Imaging VNA and XERO^® platform on AWS creates a real-time federated imaging health record across distributed and affiliated health providers. Also, please stop by for our Belgian Beer Tasting, Tuesday, April 18 and Wednesday, April 19, beginning at 4:00 PM.

About AGFA HealthCare

AGFA HealthCare supports leading healthcare providers to maximize their use of patient imaging across the enterprise-wide continuum of care. The company's Enterprise Imaging Platform delivers clinically efficient, scalable, and sustainable imaging data management.  From seamless integration and customizable workflows to cross-team collaboration and AI-powered automation, providers can deliver on business objectives and achieve organizational goals - all while enhancing productivity and keeping clinicians focused on what matters most: diagnosis and treatment for patients. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com, Agfa HealthCare News Section and follow us on LinkedIn.

AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. or its affiliates. All rights reserved. Amazon Web Services and AWS are trademarks of Amazon.com, Inc. or its affiliates.  All information contained herein is intended for guidance purposes only, and characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.

Contact Information:
Miriam Ladin
Marketing and Communication Americas
[email protected]
+1 978 284 7777


Original Source: AGFA HealthCare Joins the AWS Partner Network

Blue Goat's simple bundled cybersecurity offerings (crawl, walk, and run packages) are based on an organization's cybersecurity maturity level and Blue Goat's experience effectively reducing cybersecurity risk.

CHEYENNE, Wyo., April 11, 2023 (Newswire.com) - Blue Goat Cyber, a veteran-owned cybersecurity services provider, announced its new Cybersecurity Packages (Crawl, Walk, and Run). These cybersecurity bundles simplify cybersecurity for SMBs. Organizations can choose a package based on their cybersecurity maturity level, budget, and compliance needs.

"Our aim is to prevent cybercrime against SMBs, which are vital to our economy. Cybersecurity is often confusing, costly, and ineffective. Blue Goat's Cybersecurity Packages are simple, cost-effective, and proven," says Christian Espinosa, CEO at Blue Goat Cyber.

Features and benefits of Blue Goat's Cybersecurity Packages include:

• Coverage of the three primary attack surfaces: external environment, internal environment, and company staff
• Each package includes penetration testing, phishing, wireless testing, and more
• A Remediation Validation Test (RVT) is included to ensure that identified gaps are closed
• Each package can be performed remotely, eliminating travel costs and client time commitments

Blue Goat's Cybersecurity Packages are available immediately and start at $7750. 

For more information on Blue Goat's Cybersecurity Packages, visit: https://bluegoatcyber.com/cybersecurity-packages

About Blue Goat Cyber

Blue Goat Cyber is your trusted cybersecurity partner. Our purpose is simple - to make your organization secure. Our cybersecurity services serve this purpose. We're small enough to take real pride in each and every job we do and agile enough to take on projects of all sizes. We are always up for a challenge. We take pride in bringing order to chaos and tangible results to difficult circumstances. We realize cybersecurity is probably not the main focus of your business and is often viewed as a "necessary evil." We are not a "one-and-done" company. We value long-term relationships where we help you protect your data.

Contact Information:
Dinia Reeves
Account Executive
[email protected]
(307) 317-8884
Related Files
Blue Goat Cyber Package Offerings.pdf
Blue Goat Cyber Company Overview.pdf



Original Source: Blue Goat Cyber Develops Simple Cybersecurity Packages to Help SMBs Cost-Effectively Stop Cybercrime

NEW YORK, April 11, 2023 (Newswire.com) - Oncolyze, which already holds an Orphan Drug Designation for its lead drug candidate OM-301 in treating acute myeloid leukemia (AML), is pleased to announce that the FDA has just granted OM-301 its second Orphan Drug Designation, for multiple myeloma. 

There are approximately 35,000 cases of multiple myeloma yearly in the U.S. The five-year survival rate for multiple myeloma is about 50%. Resistance to therapy is the primary challenge associated with relapse and recurrence of multiple myeloma, especially in elderly patients. The mainstays of treatment have been agents that affect the immune system, such as Revlimid® (BMS) used in combination with the generic corticosteroid dexamethasone. The prescribing of proteasome inhibitors such as Kyprolis® (Amgen / Ono) and Ninlaro® (Takeda), along with the emergence of novel drugs such as Darzalex® (Genmab / Janssen), is having an impact on treatment choices in the third-line setting.

Research has shown that OM-301 is effective against multiple myeloma. In vitro, OM-301 was effective against eight multiple myeloma cell lines including p53 mutated and null cell lines, and it prolonged survival in an in vivo proof of concept study.

Oncolyze has recently launched a Regulation A+ ("Reg A+") funding campaign to finance the company through the FDA pathway and to clinical trials; the company is spreading awareness of OM-301 among cancer patients, healthcare professionals, and the investment community. Regulation A+ is a type of offering that allows anyone to invest in Oncolyze and receive shares in the company. The investment opportunity is being hosted by StartEngine and investments may be made in Oncolyze directly by visiting the StartEngine website. Potential investors can also learn more about the investment opportunity at the Oncolyze website.

ABOUT ONCOLYZE, INC.

Oncolyze is developing a disruptive technology for the treatment of cancer. Our lead drug candidate, OM-301, has a simple mechanism of action to selectively kill cancer cells and cancer stem cells while sparing normal cells. This can provide a highly effective treatment with potentially little to no side effects. Our initial therapeutic target is AML. Most AML patients relapse within 1 year of treatment, as standard therapy is not very effective in destroying cancer stem cells. As a result, AML has only a 25% 5-year survival rate. In contrast, OM-301 has been shown to kill leukemic cancer stem cells, which has the potential to disrupt current medical treatment. Following our proof of concept in AML, we expect to pursue development for patients with other hematologic and solid cancers; multiple myeloma is a likely target for a following clinical trial.

For more information on Oncolyze, please visit the company's website and follow us on LinkedIn.

You should read the Offering Circular and Risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA/SIPC.  This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.  

This press release may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company's actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.

Contact Information:
Mika Stojanovic
Managing Partner, TNG Creative LLC
[email protected]


Original Source: Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Multiple Myeloma

Rapha Dental LLC announces in-office teeth whitening discount promotion during the months of June and July 2023.

CINNAMINSON, N.J., April 11, 2023 (Newswire.com) - Rapha Dental LLC, a general dentist in Cinnaminson, New Jersey, is pleased to announce its teeth whitening discount promotion to be held every Tuesday during June and July 2023. 

Rapha Dental, owned and run by Dr. Huh, offers a wide selection of cosmetic, preventative, and restorative dental services, including dental implants, root canals, pediatrics, and teeth whitening. 

Patients looking to improve their smile with Rapha Dental's teeth whitening service will love the results they get with the revolutionary Zoom Teeth Whitening service offered by Philips. The treatment, usually priced at $400, will be discounted every Tuesday during June and July to $300. This $100 saving makes achieving a dazzling white and bright smile so much more affordable for many patients. 

There are many benefits to choosing Rapha Dental's teeth whitening service, including:

• Simple and non-invasive whitening procedure
• Suitable for sensitive teeth
• Quick and painless
• Highly effective results

The Zoom Teeth Whitening service can whiten the smile by up to eight shades in just 45 minutes. Patients could arrange an appointment in their lunch hour and go back to work with beautifully sparkling teeth. This treatment is affordable, too, and even more so thanks to the June and July whitening promotion. 

Dr. Mark Huh, the owner of Rapha Dental, said, "We are delighted to be able to offer more patients our revolutionary and highly effective teeth whitening service. We've helped so many of our patients to experience the confidence that a brighter, whiter smile can bring. We're looking forward to doing the same for more customers throughout our promotional period and beyond."

Patients must have a dental exam, x-ray, and teeth cleaning before having their teeth whitened. This will ensure their smile is suitable for teeth whitening and help them to achieve ultimate results from the treatment. Teeth cleaning can also be arranged on a Tuesday as part of Rapha Dental's hygiene schedule.

All treatments will be carried out by Rapha Dental's friendly and highly trained and experienced team. The treatment is safe, fast, and highly effective. The chairside service, brought to patients by Philips, provides teeth whitening at a fraction of the cost of other treatments. During June and July, patients can save even more on improving their smile. 

About Rapha Dental

Based in Cinnaminson, New Jersey, Rapha Dental LLC offers a wide selection of dental services to its patients. Patients can book an appointment using the online booking service or by calling the office at 856-829-8668.

Contact Information:
Mark Huh
Owner
[email protected]
8568298668


Original Source: Rapha Dental Announces Teeth Whitening Promotion in June and July

Vizzia Identified as Best in Class in the Real-Time Location Systems (RTLS) Industry

ATLANTA, April 11, 2023 (Newswire.com) - Vizzia Technologies, a leading software and managed service provider of real-time location systems (RTLS) for healthcare organizations, recently received the 2023 North American Company of the Year Award in the RTLS industry by the influential research firm Frost & Sullivan.

Frost & Sullivan's prestigious Company of the Year Award is its top honor and recognizes the market participant that exemplifies visionary innovation, market-leading performance and unmatched customer care. The award highlights Vizzia's unique customer service, which the company has the highest customer retention rate in the industry.

"Vizzia enjoys strong brand equity as a leading provider of RTLS solutions to healthcare facilities and is the only company that offers an end-to-end value chain proposition in the RTLS industry," remarked Bhaskar Vittal, industry principal at Frost & Sullivan. "The company provides hardware, software, and support services, making it a one-stop-shop provider for hospitals' asset management needs."

Frost & Sullivan analysts independently evaluated Vizzia on the following criteria:

• Visionary Innovation & Performance - addressing unmet needs, visionary scenarios through mega trends, leadership focus, best practices implementation and financial performance.
• Customer Impact - price/performance value, customer purchase experience, customer ownership experience, customer service experience and brand equity.

In its evaluation, Frost & Sullivan noted Vizzia's focus on optimizing medical device asset management for acute care hospitals and its precise customer service methodology. Also mentioned were new RTLS projects for Children's Healthcare of Atlanta, Grady Health System and Piedmont Healthcare.

A complimentary copy of the Frost & Sullivan best practices report is available here.

"Vizzia is honored to be recognized by Frost & Sullivan for our industry best practices," said Jim Forbes, Chief Strategy Officer of Vizzia Technologies. "The value we deliver to our customers with innovative solutions and superior support has greatly contributed to this award."

Meet Vizzia executives and partners at the HIMSS23 global conference in Chicago (April 17-21). Please contact us to schedule a meeting: [email protected]

About Vizzia Technologies

Vizzia is a recognized leader in advanced real-time location systems (RTLS) and data analytics for healthcare organizations. Its award-winning InVIEW℠ software platform provides real-time, actionable data and process visibility to improve enterprise efficiencies and patient care. Founded in 2005, Vizzia serves several of the largest hospitals and health systems in America. For more information, please visit VizziaTech.com.

Media Contact: (855) 849-9421, [email protected]

Contact Information:
Jim Forbes
Chief Strategy Officer
[email protected]
+1-855-849-9421
Related Images


Original Source: Vizzia Technologies Earns the Frost & Sullivan 2023 Company of the Year Award

The program will enable heart disease patients to participate in home-based recovery

NEW YORK, April 11, 2023 (Newswire.com) - Recora today announced its partnership with Cardiovascular Institute of Scottsdale to offer virtual cardiac rehabilitation for heart disease patients. The program adds to the robust suite of services CVI Scottsdale provides to heart disease patients, creating a new, innovative way to expand access for patients and allow them to recover from home in a virtual environment.

"As our practice continues to evolve and identify ways to better serve our patients, it seemed a natural fit to introduce Recora's Virtual Recovery Program to our market," said Dr. Nassim Haddad, Cardiologist, CVI Scottsdale. "Home-based cardiac rehab is proven to increase participation and improve outcomes, and we are excited about the possibilities this program can deliver to help our patients better their lives."

Recora will provide virtual tools for CVI Scottsdale's patients that can be accessed from the comfort of their own home, removing issues patients face with transportation and scheduling that prevent them from being able to access center-based care, along with on-demand support from care teams, 24/7 chat, and additional resources available throughout the program.

"Recora is fortunate to work with many leading health systems and practices throughout the United States, and our partners at CVI Scottsdale are as dedicated as any to their patient's cardiovascular health and care," said Recora CEO Abhishek Chandra. "Expanding our program to the Arizona community is an intriguing challenge for our team, and we look forward to the opportunities this will bring to heart disease patients in search of the right rehab program to meet their needs."

Recora's Cardiac Recovery Program has garnered industry-leading results that include:

• 15% hospital readmission rate for Recora patients, versus the national average of 43% across Medicare patients with heart failure at six months.
• 87% Recora cardiac recovery program completion rate, versus the national average of 26%. 
• 80% of patients with hypertension markedly improved their blood pressure due to diet and exercise
• 94% of Recora patients adhere to their cardiac medication.
• 80% improvement of distance and strength gains among Recora patients.

ABOUT RECORA

Recora's mission is to redefine the future of heart health. Recora's Cardiac Recovery Program for health systems, medical groups and health plans makes it easier to recover from a cardiac event through immersive programs delivered online. With Recora, healthcare providers are able to establish a longitudinal relationship with patients and help them live longer, fuller lives. To learn more, visit recora.com. 

ABOUT CARDIOVASCULAR INSTITUTE OF SCOTTSDALE

Cardiovascular Institute of Scottsdale (CVIS) was created in 2012 as a team of experts dedicated to the treatment and prevention of heart disease and vascular conditions using the most up-to-date, modern, and evidence-based treatments and medications. The care team provides a personalized and comprehensive treatment plan that incorporates an emphasis on diet, exercise, and overall healthy habits. The goal is to optimize the cardiac risk to prevent future cardiovascular events. When patients present with problems that may be cardiovascular in nature, we determine the most likely diagnosis and formulate a treatment plan and follow-up strategy that is tailored for every patient based on their profile and risk factors.

Contact Information:
Adam Hritzak
Director of Marketing, Recora
[email protected]
614-946-7916

Ilene Klein
COO
[email protected]
480-747-6532


Original Source: Recora and Cardiovascular Institute of Scottsdale Announce Virtual Cardiac Rehabilitation Partnership